An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Informazioni relative al progetto

Fucoderm

ID dell’accordo di sovvenzione: 744737

DOI

10.3030/744737

Progetto chiuso

Data della firma CE 6 Dicembre 2016

Data di avvio 1 Dicembre 2016

Data di completamento 31 Marzo 2017

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

GLYCOMAR LIMITED
United Kingdom

Periodic Reporting for period 1 - Fucoderm (An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract)

Periodo di rendicontazione: 2016-12-01 al 2017-03-31

Sintesi del contesto e degli obiettivi generali del progetto

GlycoMar intends to develop a novel topical cream for the management of mild to moderate eczema. The new product, ‘Fucobase’ will be suitable for long-term use and safe for both adults and children. The key objectives of the project are to finalise the Fucobase formulation, validate its safety and efficacy in humans, and commercialise the product as a CE certified medical device.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Throughout the duration of the Phase I project, GlycoMar reviewed the product development plan, secured partners for further product development, expanded their knowledge of the eczema market and established a commercialisation strategy. The Phase 1 feasibility assessment established that a development plan for the Fucobase product is technically and commercially viable, and that implementation of an industrialisation and commercialisation plan should be pursued. SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The proposed Fucobase product will provide mild to moderate eczema sufferers, with an effective, natural and universal treatment. Unlike many existing products, it will be suitable for use in both adults and children, due to minimal side effects. Fucobase will therefore contribute to a sustainable and innovative healthcare system in Europe by reducing the large medical and social costs caused by this common disease.

Fucobase